Legal Notices

This website is provided by Incyte Corporation ("Incyte").

PLEASE READ AND REVIEW THE FOLLOWING TERMS CAREFULLY BEFORE USING THE WEBSITE. The following terms govern your use of the website, and by using the website you agree to be bound by and to comply with such terms. If you do not agree, you may not access or use the website. Incyte reserves the right to modify these terms from time to time without notice.

Information submitted to Incyte

Should you submit any information (eg feedback, suggestions, ideas or comments) to Incyte via the website, such information, except for personally identifiable information which is covered by Incyte's Privacy Policy, will be deemed to be Incyte's property and non-confidential; and Incyte shall be free to use, reproduce, disseminate, distribute and otherwise exploit such information without limitation, and without providing any compensation to you. Incyte shall be free to use any ideas, concepts, know-how, techniques or methods contained in such information for any purpose, and in any manner, whatsoever. By submitting such information you warrant and represent that you are the owner of all rights in such information. Under no circumstances shall you use the website or any of Incyte's email or other addresses to send Incyte proprietary or confidential information belonging to a third party.

Privacy policy

See Incyte's Privacy Policy for the terms and disclosures relating to the collection and use of your personal information.

No offer and no solicitation

The information provided on the website does not constitute an, and is not provided in relation to any, offer of or solicitation for the purchase or disposal of, trading or any transaction in any Incyte securities. Investors must not rely on this information when making investment decisions.

Forward-looking statements

The website may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, except for the historical information contained therein, the matters set forth in Incyte press releases and announcements are also forward-looking statements. These statements relate to future periods, future events or our future operating or financial plans or performance. These statements can often be identified by the use of forward-looking terminology such as "expects," "believes," "intends," "anticipates," "estimates," "plans," "may," or "will," or the negative of these terms, and other similar expressions. These forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from those projected. For a discussion of some of the factors that may cause results to differ, see Incyte's reports filed with the Securities and Exchange Commission. Incyte disclaims any intent or obligation to update these forward-looking statements. You should not place undue reliance on these forward-looking statements.


Incyte reserves the right to change the content of the website at any time without notice to you. Incyte reserves the right to terminate your access or use of the website at any time. If your violation of these terms causes harm to others, you shall indemnify and hold Incyte harmless from and against any and all liabilities, losses, damage and expenses related thereto. These terms shall be governed by the laws of the State of Delaware, without giving effect to its conflict of laws principles. You hereby submit to the jurisdiction of the state and federal courts in Wilmington, Delaware in any proceeding relating to the website or its contents. These terms set forth the entire agreement between you and Incyte with respect to the subject matter hereof.

Expand Collapse



Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.